Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anatomic Stage I Breast Cancer AJCC v8: early-phase trial registry
35 of 64 indexed Anatomic Stage I Breast Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 35 currently recruiting · #215 of 28,707 conditions by registered trial count
Anatomic Stage I Breast Cancer AJCC v8: 64 US clinical trials tracked, 35 recruiting.
Anatomic Stage I Breast Cancer AJCC v8 is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.
Enrollment posture brief
Registry condition anatomic-stage-i-breast-cancer-ajcc-v8
OPEN 35 | RECR 55% | LATE 7 | EARLY 19 | RANK #215 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Hidradenitis Suppurativa (55% recruiting · 53 trials)
Anatomic Stage I Breast Cancer AJCC v8 lists 35 open slots (55% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anatomic Stage I Breast Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anatomic Stage I Breast Cancer AJCC v8 is recruiting above its size-band peers.
35 of 64 indexed trials (54.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anatomic Stage I Breast Cancer AJCC v8 research.
M.D. Anderson Cancer Center accounts for 12 of 64 trials (18.8%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Anatomic Stage I Breast Cancer AJCC v8 enrolment sits around 88 participants.
Median target enrolment is 88 among the 64 trials that report a genuine target (sentinel values excluded). 34 of those (53.1%) plan for fewer than 100 participants.
-
Anatomic Stage I Breast Cancer AJCC v8 research is mostly interventional.
56 interventional and 8 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 1 of 2
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
SWOG Cancer Research Network
NCT05929768
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Alliance for Clinical Trials in Oncology
NCT06876714
Breast Cancer Survivorship Biorepository
University of Southern California
NCT05786664
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
NCT05812807
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
Fred Hutchinson Cancer Center
NCT05930483
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
University of Southern California
NCT07259304
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
Mayo Clinic
NCT04517838
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
City of Hope Medical Center
NCT06763328
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
City of Hope Medical Center
NCT06042569
Breast Cancer, Reasoning, and Activity Intervention
Mayo Clinic
NCT04816006
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
Emory University
NCT06534125
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
NCT06635980
Integrative Approaches for Cancer Survivorship (IACS3)
University of California, San Francisco
NCT06633926
The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
Ohio State University Comprehensive Cancer Center
NCT07341503
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
Jonsson Comprehensive Cancer Center
NCT05595499
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
City of Hope Medical Center
NCT06954831
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
University of Michigan Rogel Cancer Center
NCT07158021
Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
Mayo Clinic
NCT05417867
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
University of Washington
NCT05183828
Neoadjuvant Breast Cancer Time Restricted Eating
Thomas Jefferson University
NCT05327608
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05417308
A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment
University of Alabama at Birmingham
NCT05243056
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05677802
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Emory University
NCT05464810
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
Mayo Clinic
NCT07044310
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
NCT06538389
Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment
M.D. Anderson Cancer Center
NCT05928325
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
Emory University
NCT05488145
Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors
University of Alabama at Birmingham
NCT05452681
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
Emory University
NCT05368428
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
NCT04329065
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
Mayo Clinic
NCT06401889
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
Mayo Clinic
NCT06153836
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
NCT06324240
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
M.D. Anderson Cancer Center
NCT02918474
Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer
M.D. Anderson Cancer Center
NCT04678414
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
SWOG Cancer Research Network
NCT03939481
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Alliance for Clinical Trials in Oncology
NCT04379570
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT01334021
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
SWOG Cancer Research Network
NCT05568472
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
Alliance for Clinical Trials in Oncology
NCT04549571
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT04906200
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
Thomas Jefferson University
NCT04086875
Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
M.D. Anderson Cancer Center
NCT04754412
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
ECOG-ACRIN Cancer Research Group
NCT04001829
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
Mayo Clinic
NCT04443413
Metformin and Nightly Fasting in Women With Early Breast Cancer
M.D. Anderson Cancer Center
NCT05023967
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
M.D. Anderson Cancer Center
NCT07407920
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
Rutgers, The State University of New Jersey
NCT04871516
Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT05049746
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 14 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Anatomic Stage I Breast Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anatomic Stage I Breast Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anatomic Stage I Breast Cancer AJCC v8 page
64 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 35 Anatomic Stage I Breast Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Anatomic Stage I Breast Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anatomic Stage I Breast Cancer AJCC v8 condition card totals 64 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.